2023
A pilot randomized controlled trial of ketamine in Borderline Personality Disorder
Fineberg S, Choi E, Shapiro-Thompson R, Dhaliwal K, Neustadter E, Sakheim M, Null K, Trujillo-Diaz D, Rondeau J, Pittaro G, Peters J, Corlett P, Krystal J. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology 2023, 48: 991-999. PMID: 36804489, PMCID: PMC10209175, DOI: 10.1038/s41386-023-01540-4.Peer-Reviewed Original ResearchConceptsBorderline personality disorderSecondary outcome measuresOutcome measuresSocio-occupational functioningSuicidal ideationPilot studyTrial of ketaminePersonality disorderInfusion of ketaminePrimary outcome measureEffects of ketamineMidazolam groupAdverse eventsKetamine groupClinical benefitMood symptomsKetamineFDA approvalDrug midazolamInfusionBPD symptomsLarger studyDepressed moodSymptomsChronic mood
2014
Is Prevention a Realistic Goal for Schizophrenia?
Kohler C, Borgmann-Winter K, Hurford I, Neustadter E, Yi J, Calkins M. Is Prevention a Realistic Goal for Schizophrenia? Current Psychiatry Reports 2014, 16: 439. PMID: 24566772, DOI: 10.1007/s11920-014-0439-y.Peer-Reviewed Original ResearchConceptsEarly clinical symptomsOnset of psychosisCertain clinical presentationsLarge epidemiological studiesClinical presentationClinical symptomsClinical riskEpidemiological studiesSchizophrenia phenotypePsychosisMultidisciplinary approachRisk stateSchizophreniaRealistic goalsRecent studiesOnsetSymptomsPrevention